Company Announcements
Director/PDMR Shareholding
Related Companies
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||
|
a) |
Name |
Sir Andrew Witty |
||||||||||||||||||||||
|
b) |
Position/status |
Chief Executive Officer |
||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
3,463.948 £15.66 |
||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Ms E Walmsley |
||||||||||||||||||||||||||
|
b) |
Position/status |
CEO Designate |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,343.746 £15.66 |
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||
|
a) |
Name |
Mr R G Connor |
||||||||||||||||||||||
|
b) |
Position/status |
President, Global Manufacturing & Supply |
||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
765.45 £15.66
|
||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Mr S Dingemans |
||||||||||||||||||||||||||
|
b) |
Position/status |
Chief Financial Officer |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,863.862 £15.66
|
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||
|
a) |
Name |
Mr N Hirons |
||||||||||||||||||
|
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
489.132 £15.66 |
||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||
|
a) |
Name |
Mr S A Hussain |
||||||||||||||||||
|
b) |
Position/status |
President, Global Pharmaceuticals |
||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,388.538 £15.66 |
||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Mr D S Redfern |
||||||||||||||||||||||||||
|
b) |
Position/status |
Chief Strategy Officer |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
960.986 £15.66 |
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Dr M M Slaoui |
||||||||||||||||||||||||||
|
b) |
Position/status |
Chairman, Global Vaccines |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,327.422 $39.01 |
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||
|
a) |
Name |
Ms C Thomas |
||||||||||||||||||||||
|
b) |
Position/status |
SVP, Human Resources |
||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,133.866 £15.66
|
||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||
|
a) |
Name |
Mr P C Thomson |
||||||||||||||
|
b) |
Position/status |
SVP, Communications & Government Affairs |
||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
410.864 £15.66 |
||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Mr D E Troy |
||||||||||||||||||||||||||
|
b) |
Position/status |
SVP & General Counsel |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
728.176 $39.01
|
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||||||||||||||||||
|
a) |
Name |
Dr P J T Vallance |
||||||||||||||||||||||||||
|
b) |
Position/status |
President, Pharmaceuticals R&D |
||||||||||||||||||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||||||||||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||||||||||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||||||||||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||||||||||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. |
||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,858.758 £15.66 |
||||||||||||||||||||||||||
|
e) |
Date of the transaction |
2017-01-12 |
||||||||||||||||||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||||||||||||||||||
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN